Addressing some of the key challenges in translational science, such as increasing the reproducibility of preclinical research and reducing the failure rate of drugs in development, requires a collaborative approach. On December 9th and 10th, NIH-NCATS hosted the first meeting of a new collaboration among leading translational science organizations including CDRD (the only Canadian organization at the meeting), the European Infrastructure for Translational Medicine and Therapeutic Innovation Australia. This “Translational Science on the Global Stage” event was a two-day meeting in Bethesda, Maryland.
The purpose of the gathering had two primary objectives: (1) become acquainted with the mission, structure and activities of each organization, and (2) explore how we could collectively address some of the most significant hurdles in bringing new medicines to more patients, more efficiently. Each organization presented snapshots of their efforts to overcome these barriers and shared best practices so that each could learn from each other’s experiences.
CDRD was represented by Dr. Gregorio Aversa, Senior Vice President, Drug Development and Dr. Michael Underhill, Co-Scientific Director and Division Chair, Target Validation. They shared how CDRD’s unique model specifically created to de-risk promising discoveries stemming from publicly-funded academic health research, is transforming research into commercially viable opportunities for the private sector. By providing specialized expertise and infrastructure, conducting critical proof-of-concept studies, CDRD is bridging the gap between academia and industry for the ultimate benefit of patients.
The collaborators recognized common experiences and challenges and will continue to work together on the fundamental principles to improve translational science on a global scale and will coordinate opportunities for collective organizational growth.